2020
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort study
2016
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis
2009
ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
SETH RK, SALIM S, SHIELDS MB, ADELMAN RA. ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. Retina 2009, 29: 956-959. PMID: 19584654, DOI: 10.1097/iae.0b013e3181a91dfd.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideDrug Therapy, CombinationEyeFollow-Up StudiesFundus OculiHumansInjectionsIntraocular PressureOptic DiskOptic NerveRanibizumabRegional Blood FlowRetrospective StudiesSingle-Blind MethodVascular Endothelial Growth Factor AVitreous BodyConceptsMultiple intravitreal injectionsAnti-VEGF agentsIntraocular pressure riseIntraocular pressure fluctuationIntravitreal injectionMean changeControl groupTransient intraocular pressure riseSignificant differencesDisc ratio changesOptic nerve cupHistory of glaucomaAdditional prospective studiesGrowth factor effectsFellow eyesGlaucoma specialistsOptic nerveProspective studyOptic disc imagesFundus photographsTriamcinolone acetonideInclusion criteriaDisc ratioVertical cupPatients
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply